Bahram Valamehr, Chief R&D Officer at FATE THERAPEUTICS INC (FATE), sold 49,900 shares at $30.36 ($1.6M) on 2022-03-14, disclosed to the SEC on 2022-03-15.
Open-market sale of $1.6M FATE by Chief R&D Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.36 | 16,678 | $506K | 32.7% |
| 2 | $30.36 | 16,678 | $506K | 32.7% |
| 3 | $31.66 | 3,067 | $97K | 6.3% |
| 4 | $31.66 | 3,067 | $97K | 6.3% |
| 5 | $32.49 | 2,195 | $71K | 4.6% |
| 6 | $32.49 | 2,195 |
| $71K |
| 4.6% |
| 7 | $33.30 | 2,960 | $99K | 6.4% |
| 8 | $33.30 | 2,960 | $99K | 6.4% |
| 9 | $34.04 | 100 | $3K | 0.2% |
| Total | $31.06 avg | 49,900 | $1.6M | 100% |
| Filing → |
| FATE | SELL | 2026-01-12 | $6K | — | Filing → |
| FATE | SELL | 2025-08-05 | $15K | — | Filing → |
| FATE | SELL | 2025-01-13 | $13K | — | Filing → |